$LUMO
Lumos Pharma Inc

2019 Q4 Form 10-Q Financial Statement

#000112623419000142 Filed on November 06, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q4
Revenue $433.0K $0.00 $202.0K
YoY Change 114.36% -100.0% -98.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.100M $1.500M $5.400M
YoY Change -79.63% -77.94% -3.57%
% of Gross Profit
Research & Development $2.400M $1.202M $5.700M
YoY Change -57.89% -84.12% -66.27%
% of Gross Profit
Depreciation & Amortization $1.600M $0.00 $200.0K
YoY Change 700.0% -100.0% -33.33%
% of Gross Profit
Operating Expenses $3.500M $2.698M $11.10M
YoY Change -68.47% -82.2% -50.45%
Operating Profit -$8.689M -$2.698M -$10.95M
YoY Change -20.62% -82.06% -22.1%
Interest Expense $400.0K $0.00 $500.0K
YoY Change -20.0% -100.0% 66.67%
% of Operating Profit
Other Income/Expense, Net $0.00 $29.00K -$100.0K
YoY Change -100.0% -95.5%
Pretax Income -$8.300M -$2.669M -$10.50M
YoY Change -20.95% -81.46% -23.91%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.271M -$2.669M -$10.57M
YoY Change -21.74% -63.95% -22.78%
Net Earnings / Revenue -1910.16% -5232.18%
Basic Earnings Per Share -$0.22 -$2.56 -$0.28
Diluted Earnings Per Share -$2.024M -$2.56 -$2.585M
COMMON SHARES
Basic Shares Outstanding 37.31M shares 1.343M shares 37.22M shares
Diluted Shares Outstanding 1.343M shares

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.000M $98.50M $120.7M
YoY Change -95.86% -19.33% -23.94%
Cash & Equivalents $5.000M $98.53M $120.7M
Short-Term Investments
Other Short-Term Assets $100.0K $3.300M $5.500M
YoY Change -98.18% -32.65% -11.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables $35.00K $740.0K $459.0K
Total Short-Term Assets $5.069M $102.7M $127.1M
YoY Change -96.01% -24.0% -27.58%
LONG-TERM ASSETS
Property, Plant & Equipment $84.00K $2.889M $3.727M
YoY Change -97.75% -29.47% -26.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $457.0K $4.000M $3.867M
YoY Change -88.18% -5.57% -26.08%
TOTAL ASSETS
Total Short-Term Assets $5.069M $102.7M $127.1M
Total Long-Term Assets $457.0K $4.000M $3.867M
Total Assets $5.526M $106.7M $130.9M
YoY Change -95.78% -23.44% -27.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $365.0K $145.0K $555.0K
YoY Change -34.23% -88.29% -94.0%
Accrued Expenses $709.0K $12.13M $8.139M
YoY Change -91.29% 38.79% -34.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $100.0K $100.0K
YoY Change -100.0% 0.0% -50.0%
Total Short-Term Liabilities $1.263M $14.04M $8.847M
YoY Change -85.72% 38.57% -59.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $200.0K $6.200M $6.900M
YoY Change -97.1% -10.14% -1.43%
Total Long-Term Liabilities $191.0K $6.217M $6.949M
YoY Change -97.25% -11.03% -2.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.263M $14.04M $8.847M
Total Long-Term Liabilities $191.0K $6.217M $6.949M
Total Liabilities $1.454M $20.26M $15.80M
YoY Change -90.8% 18.32% -45.79%
SHAREHOLDERS EQUITY
Retained Earnings -$59.68M -$325.7M -$291.0M
YoY Change -79.49% 16.15% 22.55%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00 $1.451M $1.417M
YoY Change -100.0% 2.98% 24.08%
Treasury Stock Shares 176.6K shares 112.8K shares 92.33K shares
Shareholders Equity -$59.46M -$56.40M -$46.92M
YoY Change
Total Liabilities & Shareholders Equity $5.526M $106.7M $130.9M
YoY Change -95.78% -23.44% -27.54%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q4
OPERATING ACTIVITIES
Net Income -$8.271M -$2.669M -$10.57M
YoY Change -21.74% -63.95% -22.78%
Depreciation, Depletion And Amortization $1.600M $0.00 $200.0K
YoY Change 700.0% -100.0% -33.33%
Cash From Operating Activities -$23.80M -$1.900M -$1.300M
YoY Change 1730.77% -87.33% -92.44%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $100.0K $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $100.0K $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -100.0K 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -23.80M -1.900M -1.300M
Cash From Investing Activities 100.0K 0.000 0.000
Cash From Financing Activities -100.0K 0.000 0.000
Net Change In Cash -23.80M -1.900M -1.300M
YoY Change 1730.77% -87.33% -103.41%
FREE CASH FLOW
Cash From Operating Activities -$23.80M -$1.900M -$1.300M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$23.80M -$1.900M -$1.300M
YoY Change 1730.77% -87.33% -92.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001126234
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35342
dei Entity Registrant Name
EntityRegistrantName
NEWLINK GENETICS CORP
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
42-1491350
dei Entity Address Address Line1
EntityAddressAddressLine1
2503 South Loop Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Ames
dei Entity Address State Or Province
EntityAddressStateOrProvince
IA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
50010
dei City Area Code
CityAreaCode
515
dei Local Phone Number
LocalPhoneNumber
296-5555
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
NLNK
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37314076 shares
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98527000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120738000 USD
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3311000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5536000 USD
CY2019Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
76000 USD
CY2018Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
339000 USD
CY2019Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
740000 USD
CY2018Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
459000 USD
CY2019Q3 us-gaap Assets Current
AssetsCurrent
102654000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
127072000 USD
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2889000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3727000 USD
CY2019Q3 nlnk Operating Lease Rightof Use Asset Noncurrent
OperatingLeaseRightofUseAssetNoncurrent
1042000 USD
CY2018Q4 nlnk Operating Lease Rightof Use Asset Noncurrent
OperatingLeaseRightofUseAssetNoncurrent
0 USD
CY2019Q3 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
69000 USD
CY2018Q4 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
140000 USD
CY2019Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
4000000 USD
CY2018Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
3867000 USD
CY2019Q3 us-gaap Assets
Assets
106654000 USD
CY2018Q4 us-gaap Assets
Assets
130939000 USD
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
145000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
555000 USD
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12125000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8139000 USD
CY2019Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
0 USD
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
92000 USD
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1712000 USD
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 USD
CY2019Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
58000 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
61000 USD
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14040000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8847000 USD
CY2019Q3 nlnk Deferred Government Grants Obligations Noncurrent
DeferredGovernmentGrantsObligationsNoncurrent
6000000 USD
CY2018Q4 nlnk Deferred Government Grants Obligations Noncurrent
DeferredGovernmentGrantsObligationsNoncurrent
6000000 USD
CY2019Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
0 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
43000 USD
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
217000 USD
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2019Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
0 USD
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
906000 USD
CY2019Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6217000 USD
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6949000 USD
CY2019Q3 us-gaap Liabilities
Liabilities
20257000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
15796000 USD
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q3 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2018Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37426844 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37343547 shares
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37314076 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37251220 shares
CY2019Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
373000 USD
CY2018Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
373000 USD
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
413205000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
407199000 USD
CY2019Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
112768 shares
CY2018Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
92327 shares
CY2019Q3 us-gaap Treasury Stock Value
TreasuryStockValue
1451000 USD
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1417000 USD
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-325730000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-291012000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
86397000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
115143000 USD
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
106654000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
130939000 USD
CY2019Q3 us-gaap Revenues
Revenues
246000 USD
CY2018Q3 us-gaap Revenues
Revenues
120000 USD
us-gaap Revenues
Revenues
503000 USD
us-gaap Revenues
Revenues
12272000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7024000 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7570000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17464000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39972000 USD
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8279000 USD
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7588000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19484000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23792000 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
15303000 USD
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
15158000 USD
us-gaap Operating Expenses
OperatingExpenses
36948000 USD
us-gaap Operating Expenses
OperatingExpenses
63764000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15057000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15038000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-36445000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-51492000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-33000 USD
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-38000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16000 USD
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
567000 USD
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
664000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
1815000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
1510000 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
25000 USD
CY2018Q3 us-gaap Interest Expense
InterestExpense
2000 USD
us-gaap Interest Expense
InterestExpense
50000 USD
us-gaap Interest Expense
InterestExpense
51000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
509000 USD
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
644000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1727000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1475000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14548000 USD
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14394000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34718000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-50017000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6991000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6991000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-14548000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-7403000 USD
us-gaap Net Income Loss
NetIncomeLoss
-34718000 USD
us-gaap Net Income Loss
NetIncomeLoss
-43026000 USD
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.16
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37308523 shares
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37214363 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37286930 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37178542 shares
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
115143000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1944000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2019Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
32000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-10036000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
107019000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1773000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
30000 USD
CY2019Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-10134000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
98687000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2259000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2019Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-14548000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
86397000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
151557000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4820000 USD
CY2018Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
106000 USD
CY2018Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
261000 USD
CY2018Q1 us-gaap New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
42000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-18310000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
137954000 USD
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4177000 USD
CY2018Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2018Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
130000 USD
CY2018Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-17313000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
124946000 USD
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4623000 USD
CY2018Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
33000 USD
CY2018Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
4000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-7403000 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
122195000 USD
us-gaap Net Income Loss
NetIncomeLoss
-34718000 USD
us-gaap Net Income Loss
NetIncomeLoss
-43026000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
5976000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
13620000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
432000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
901000 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
351000 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-40000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
16000 USD
nlnk Finance Lease Right Of Use Asset Amortization And Change In Operating Lease Liability
FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability
111000 USD
nlnk Finance Lease Right Of Use Asset Amortization And Change In Operating Lease Liability
FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2225000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-842000 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
281000 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-9982000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3576000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-11749000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
334000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-7042000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-56000 USD
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
0 USD
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
78000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22176000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36622000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
15000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
118000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
111000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
269000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
34000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
267000 USD
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
46000 USD
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
138000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-50000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-136000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22211000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36647000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
120738000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
158708000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98527000 USD
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122061000 USD
us-gaap Interest Paid Net
InterestPaidNet
3000 USD
us-gaap Interest Paid Net
InterestPaidNet
6000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
14000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
348000 USD
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
4000 USD
us-gaap Nature Of Operations
NatureOfOperations
Description of Business<div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On June 4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed to develop treatments for patients with cancer and other diseases. NewLink initiated operations in April 2000. </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">NewLink and its subsidiaries (the Company) have historically devoted substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements as of September 30, 2019 and for the three and nine months ended September 30, 2019 have been prepared assuming the Company will continue as a going concern. </span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company’s cash and cash equivalents as of September 30, 2019 are expected to be adequate to satisfy the Company’s liquidity requirements through 2021. If available liquidity becomes insufficient to meet the Company’s operating obligations as they come due, the Company’s plans include selling additional shares of common stock, alternative funding arrangements and/or reducing expenditures as necessary to meet the Company’s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position and may materially affect the Company’s ability to continue as a going concern.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Proposed Merger with Lumos Pharma</span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On September 30, 2019, the Company, Cyclone Merger Sub, Inc., a wholly-owned subsidiary of the Company (Merger Sub), and Lumos Pharma, Inc., a privately-held Delaware corporation (Lumos), entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement), pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Lumos, with Lumos surviving as a wholly-owned subsidiary of NewLink (the Merger). Following the Merger, NewLink will change its name to “Lumos Pharma, Inc.” and Lumos will change its name to a name mutually agreed upon by the Company and Lumos. </span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">At the effective time of the Merger (Effective Time), each share of Lumos capital stock outstanding immediately prior to the Effective Time (excluding shares of Lumos capital stock held as treasury stock or held or owned by Lumos or Merger Sub prior to the Effective Time and shares held by Lumos stockholders who have exercised and perfected appraisal rights in accordance with Delaware law) shall be automatically converted solely into the right to receive a number of shares of NewLink’s common stock equal to the amount determined pursuant to a charter amendment to Lumos’ certificate of incorporation that will be filed prior to the Effective Time, at exchange ratios applicable to each type of Lumos capital stock. Pursuant to such conversion, immediately following the Merger, former Lumos stockholders will own approximately 50% of the aggregate number of shares of Company common stock issued and outstanding following the consummation of the Merger (the Post-Closing Shares), and the stockholders of the Company as of immediately prior to the Merger are expected to own approximately 50% of the aggregate number of Post-Closing Shares. Outstanding options to purchase Lumos common stock will be assumed by NewLink and converted into options to purchase a number of shares of NewLink’s common stock at the exchange ratio applicable to exchanging shares of Lumos common stock for NewLink’s common stock.</span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Merger Agreement includes customary representations, warranties and covenants made by the Company and Lumos, including covenants relating to the Company's and Lumos' conduct of their respective businesses between the date of signing the Merger Agreement and the closing of the Merger. Consummation of the Merger is subject to certain closing conditions, including, among other things, approval by the stockholders of the Company and Lumos. Lumos stockholders approved the Merger in September 2019. The Merger Agreement contains certain termination rights for both the Company and Lumos, and further provides that, upon termination of the Merger Agreement under specified circumstances, the Company or Lumos, as applicable, may be required to pay the other party a termination fee of $2.0 million.</span></div><div style="text-indent:27pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Merger Agreement contemplates that the Company will also seek approval from its stockholders to effect a reverse stock split, with the split ratio to be mutually agreed to by the Company and Lumos immediately prior to the Effective Time. The Merger is expected to close in the first quarter of 2020.</span></div>
CY2019Q3 us-gaap Subsidiary Or Equity Method Investee Cumulative Percentage Ownership After All Transactions
SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions
0.50
CY2019Q3 nlnk Merger Agreement Covenants Termination Fee Payable
MergerAgreementCovenantsTerminationFeePayable
2000000.0 USD
us-gaap Basis Of Accounting
BasisOfAccounting
Basis of Presentation<div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements have been prepared and presented by the Company in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the U.S. Securities and Exchange Commission (the SEC), and, in management’s opinion, reflect all adjustments necessary to present fairly the Company’s interim condensed financial information.</span></div><div style="text-indent:22pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2018, included in the Company’s Annual Report on Form 10-K. The financial results for any interim period are not necessarily indicative of financial results for the full year.</span></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div>
CY2019Q3 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
58000 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
104000 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high-quality securities such as certificates of deposit and money market funds.
CY2019Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7600000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7000000.0 USD
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
8500000 USD
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7500000 USD
CY2018Q4 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
1000000.0 USD
CY2019Q3 us-gaap Government Contract Receivable
GovernmentContractReceivable
520000 USD
CY2018Q4 us-gaap Government Contract Receivable
GovernmentContractReceivable
309000 USD
CY2019Q3 nlnk Government Contract Accrued Subcontractor Fees
GovernmentContractAccruedSubcontractorFees
24000 USD
CY2018Q4 nlnk Government Contract Accrued Subcontractor Fees
GovernmentContractAccruedSubcontractorFees
54000 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2300000 USD
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4600000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6000000.0 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13600000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
255000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
599000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
59330 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
CY2019Q2 nlnk Share Based Payment Arrangement Option Exchange Number Of Shares Authorized
ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized
5849059 shares
CY2019Q3 nlnk Share Based Payment Arrangement Option Exchange Number Of Participants
ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants
45 employee
CY2019Q3 nlnk Share Based Payment Arrangement Option Exchange Number Of Participants
ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants
5 director
CY2019Q3 nlnk Share Based Payment Arrangement Option Exchange Options Converted
ShareBasedPaymentArrangementOptionExchangeOptionsConverted
3914856 shares
CY2019Q3 nlnk Share Based Payment Arrangement Option Exchange Number Of Shares Authorized Converted Percent
ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent
0.67
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1720341 shares
CY2019Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.77
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P7Y
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1000000.0 USD
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
133000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
987000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9000 USD
CY2019Q3 nlnk Lessee Operating Lease Liability Unamortized Incentives
LesseeOperatingLeaseLiabilityUnamortizedIncentives
951000 USD
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1929000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1105000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1004000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
923000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
906000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
909000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
6570000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11417000 USD
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
351000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7000000.0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7000000.0 USD
CY2019Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax
DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
140000 USD
CY2019Q3 nlnk Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax Current
DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxCurrent
71000 USD
CY2019Q3 nlnk Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax Noncurrent
DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent
69000 USD
CY2019Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
653000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-14548000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-7403000 USD
us-gaap Net Income Loss
NetIncomeLoss
-34718000 USD
us-gaap Net Income Loss
NetIncomeLoss
-43026000 USD
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37308523 shares
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37214363 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37286930 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37178542 shares
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.16
CY2019Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.60
us-gaap Restructuring Charges
RestructuringCharges
4500000 USD
CY2019Q3 us-gaap Restructuring Charges
RestructuringCharges
4500000 USD
CY2019Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
351000 USD
CY2018Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.30
CY2018Q3 us-gaap Restructuring Charges
RestructuringCharges
1300000 USD
us-gaap Restructuring Charges
RestructuringCharges
1300000 USD
CY2018Q4 us-gaap Restructuring Reserve
RestructuringReserve
649000 USD
us-gaap Restructuring Charges
RestructuringCharges
4489000 USD
us-gaap Payments For Restructuring
PaymentsForRestructuring
554000 USD
CY2019Q3 us-gaap Restructuring Reserve
RestructuringReserve
4584000 USD

Files In Submission

Name View Source Status
0001126234-19-000142-index-headers.html Edgar Link pending
0001126234-19-000142-index.html Edgar Link pending
0001126234-19-000142.txt Edgar Link pending
0001126234-19-000142-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
new-2019930x10qxex101.htm Edgar Link pending
nlnk-20190930.htm Edgar Link pending
nlnk-20190930.xsd Edgar Link pending
nlnk-20190930_cal.xml Edgar Link unprocessable
nlnk-20190930_def.xml Edgar Link unprocessable
nlnk-20190930_g1.jpg Edgar Link pending
nlnk-20190930_htm.xml Edgar Link completed
nlnk-20190930_lab.xml Edgar Link unprocessable
nlnk-20190930_pre.xml Edgar Link unprocessable
nlnk-2019930x10qxex311.htm Edgar Link pending
nlnk-2019930x10qxex312.htm Edgar Link pending
nlnk-2019930x10qxex321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending